Dianthus Therapeutics Inc. Insider Trading

DNTH

Last 12 months

Insiders sold $71.2M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Sep 2023.

Net open-market

−$71.2M

0 buys · 20 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Sep 2023

Sep 29, 2023

Get an email when DNTH's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 17	Edward Carr Chief Accounting Officer	Sold10b5-1 plan 5 parts	20,000	$101.38 average	$2.03M	100%	Form 4
Sep 1	Simrat Randhawa EVP, Head of R&D	Sold10b5-1 plan 3 parts	23,124	$106.41 average	$2.46M	85%	Form 4
Aug 19	Simon Read Director	Sold10b5-1 plan	2,778	$117.55	327K	100%	Form 4
Aug 10	Anne McGeorge Director	Sold10b5-1 plan 5 parts	7,750	$109.01 average	845K	100%	Form 4
Aug 7 – 10	Adam M Veness SVP, General Counsel and Sec.	Sold10b5-1 plan 3 parts	20,000	$110.44 average	$2.21M	100%	Form 4
Aug 10	Simon Read Director	Sold10b5-1 plan 6 parts	2,777	$109.55 average	304K	100%	Form 4
Aug 7	Marino Garcia CEO and President	Sold10b5-1 plan 7 parts	166,000	$108.11 average	$17.9M	72%	Form 4
Jul 9	Ryan Savitz EVP, CFO & Cbo	Sold10b5-1 plan 3 parts	31,249	$101.03 average	$3.16M	100%	Form 4
Jun 17	Adam M Veness SVP, General Counsel and Sec.	Sold10b5-1 plan 2 parts	30,000	$80.80 average	$2.42M	100%	Form 4
Jun 1	Simrat Randhawa EVP, Head of R&D	Sold10b5-1 plan 3 parts	26,530	$90.62 average	$2.4M	87%	Form 4
May 8	Paula Soteropoulos Director	Sold10b5-1 plan	599	$85.47	51K	100%	Form 4
Apr 9	Ryan Savitz EVP, CFO & Cbo	Sold10b5-1 plan	8,224	$89.84	739K	100%	Form 4
Mar 31	Ryan Savitz EVP, CFO & Cbo	Sold10b5-1 plan 8 parts	114,367	$83.00 average	$9.49M	100%	Form 4
Mar 31	Paula Soteropoulos Director	Sold10b5-1 plan	599	$80.11	48K	100%	Form 4
Mar 24	Paula Soteropoulos Director	Sold10b5-1 plan	27,594	$78.05	$2.15M	100%	Form 4
Mar 12	Simrat Randhawa EVP, Head of R&D	Sold10b5-1 plan	33,830	$81.48	$2.76M	100%	Form 4
Mar 12	Marino Garcia CEO and President	Sold10b5-1 plan 5 parts	122,918	$81.49 average	$10M	100%	Form 4
Mar 12	Edward Carr Chief Accounting Officer	Sold10b5-1 plan 5 parts	43,682	$81.49 average	$3.56M	100%	Form 4
Dec 4, 2025	Ryan Savitz CFO & Cbo	Sold10b5-1 plan	20,000	$45.18	904K	100%	Form 4
Nov 13, 2025 – Nov 14, 2025	Simrat Randhawa EVP, Head of R&D	Sold10b5-1 plan 4 parts	196,538	$37.55 average	$7.38M	98%	Form 4
Sep 9, 2025	Ryan Savitz CFO & Cbo	Sold10b5-1 plan	20,000	$35.00	700K	100%	Form 4

Sep 1710b5-1 plan
Edward Carr
Chief Accounting Officer · sold 20,000 at avg $101.38
$2.03M
100% of stake
Sep 110b5-1 plan
Simrat Randhawa
EVP, Head of R&D · sold 23,124 at avg $106.41
$2.46M
85% of stake
Aug 1910b5-1 plan
Simon Read
Director · sold 2,778 at $117.55
327K
100% of stake
Aug 1010b5-1 plan
Anne McGeorge
Director · sold 7,750 at avg $109.01
845K
100% of stake
Aug 7 – 1010b5-1 plan
Adam M Veness
SVP, General Counsel and Sec. · sold 20,000 at avg $110.44
$2.21M
100% of stake
Aug 1010b5-1 plan
Simon Read
Director · sold 2,777 at avg $109.55
304K
100% of stake
Aug 710b5-1 plan
Marino Garcia
CEO and President · sold 166,000 at avg $108.11
$17.9M
72% of stake
Jul 910b5-1 plan
Ryan Savitz
EVP, CFO & Cbo · sold 31,249 at avg $101.03
$3.16M
100% of stake
Jun 1710b5-1 plan
Adam M Veness
SVP, General Counsel and Sec. · sold 30,000 at avg $80.80
$2.42M
100% of stake
Jun 110b5-1 plan
Simrat Randhawa
EVP, Head of R&D · sold 26,530 at avg $90.62
$2.4M
87% of stake
May 810b5-1 plan
Paula Soteropoulos
Director · sold 599 at $85.47
51K
100% of stake
Apr 910b5-1 plan
Ryan Savitz
EVP, CFO & Cbo · sold 8,224 at $89.84
739K
100% of stake
Mar 3110b5-1 plan
Ryan Savitz
EVP, CFO & Cbo · sold 114,367 at avg $83.00
$9.49M
100% of stake
Mar 3110b5-1 plan
Paula Soteropoulos
Director · sold 599 at $80.11
48K
100% of stake
Mar 2410b5-1 plan
Paula Soteropoulos
Director · sold 27,594 at $78.05
$2.15M
100% of stake
Mar 1210b5-1 plan
Simrat Randhawa
EVP, Head of R&D · sold 33,830 at $81.48
$2.76M
100% of stake
Mar 1210b5-1 plan
Marino Garcia
CEO and President · sold 122,918 at avg $81.49
$10M
100% of stake
Mar 1210b5-1 plan
Edward Carr
Chief Accounting Officer · sold 43,682 at avg $81.49
$3.56M
100% of stake
Dec 4, 202510b5-1 plan
Ryan Savitz
CFO & Cbo · sold 20,000 at $45.18
904K
100% of stake
Nov 13, 2025 – Nov 14, 202510b5-1 plan
Simrat Randhawa
EVP, Head of R&D · sold 196,538 at avg $37.55
$7.38M
98% of stake
Sep 9, 202510b5-1 plan
Ryan Savitz
CFO & Cbo · sold 20,000 at $35.00
700K
100% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch DNTH, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with DNTH

CompareIntrinsic value

LPCNLipocine Inc.

$1.44-1.37%40

ORMPOramed Pharmaceuticals Inc.

$4.13+3.25%35

CRVOCervoMed Inc.

$1.56+0.65%10

CYCNCyclerion Therapeutics Inc.

$30.56-4.38%40

NRXPNRx Pharmaceuticals, Inc.

$2.49+11.16%10

RNACCartesian Therapeutics Inc.

$6.84+6.71%10

SCPXScorpius Holdings Inc.

$0.00+0.00%10

BIOEBio Essence Corp

$0.47+0.00%80

Held by ETFs

DNTH is in 60 US ETFs. The largest of them, with DNTH's weight in each:

Spot a number that looks wrong? Check it in DNTH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DNTH

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.